Analyzing Investor Sentiment Towards Cerevel Therapeutics (CERE) Stocks

This afternoon we watched Cerevel Therapeutics drop -5.5% to a price of $39.12 per share. The Mid-Cap Pharmaceutical company is now trading -9.85% below its average target price of $43.4. Analysts have set target prices ranging from $31.0 to $45.0 per share for Cerevel Therapeutics, and have given the stock an average rating of hold.

The stock has an above average percentage of its shares sold short at 8.2%, and a short ratio of 7.39. Since 15.32% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 85.3% of Cerevel Therapeutics's shares being owned by this investor type.

Institutions Invested in Cerevel Therapeutics

Date Reported Holder Percentage Shares Value
2024-03-31 Bain Capital Investors Llc 36% 65,679,781 $2,569,721,431
2024-03-31 Perceptive Advisors Llc 6% 10,794,876 $422,349,523
2024-03-31 Avoro Capital Advisors LLC 4% 7,555,555 $295,611,089
2024-03-31 Vanguard Group Inc 4% 7,463,911 $292,025,517
2024-03-31 Blackrock Inc. 3% 5,448,620 $213,177,257
2024-03-31 State Street Corporation 2% 3,528,470 $138,051,388
2024-03-31 FIL LTD 2% 3,249,000 $127,117,125
2024-03-31 Alpine Associates Management Inc. 1% 2,341,394 $91,607,040
2024-03-31 Paradigm Biocapital Advisors LP 1% 2,330,508 $91,181,125
2024-03-31 Pentwater Capital Management Lp 1% 2,220,000 $86,857,500

Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Cerevel Therapeutics.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.